Related Experiment Video
Updated: May 18, 2026
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Clinical predictors of outcome in MPN
Francesco Passamonti1, Margherita Maffioli, Michele Merli
1Division of Hematology, Department of Internal Medicine, Ospedale di Circolo e Fondazione Macchi, Viale Borri 57, 21100 Varese, Italy. francesco.passamonti@ospedale.varese.it
Abstract:
Myeloproliferative neoplasms include 3 diseases: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). PV and ET are dominated by a high risk of thrombosis and a late risk of clonal evolution into secondary MF and acute myeloid leukemia. Patients with PMF may encounter many complications associated with disease progression or with PMF evolution. This article defines factors that determine prognosis in these 3 diseases.
Insights
Prognosis in myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), is determined by specific factors. Understanding these factors is crucial for managing thrombosis and disease progression risks.
Area of Science:
- Hematology
- Oncology
Background:
- Myeloproliferative neoplasms (MPNs) encompass polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
- PV and ET present significant risks of thrombosis and potential evolution to myelofibrosis or acute myeloid leukemia.
- Primary myelofibrosis (PMF) is associated with numerous complications due to disease progression.
Purpose of the Study:
- To define the prognostic factors for three major myeloproliferative neoplasms: PV, ET, and PMF.
- To provide a clear understanding of factors influencing patient outcomes in these hematologic malignancies.
Main Methods:
- Review of existing literature on prognostic indicators in MPNs.
- Analysis of clinical data and established risk stratification systems for PV, ET, and PMF.
Main Results:
- Identification of key factors influencing thrombosis risk in PV and ET.
- Characterization of elements contributing to disease progression and complications in PMF.
- Consolidation of prognostic markers across the spectrum of these myeloproliferative diseases.
Conclusions:
- Prognostic factors vary among PV, ET, and PMF, impacting clinical management strategies.
- Accurate assessment of prognosis is essential for optimizing patient care and monitoring for disease evolution.
- Further research into novel prognostic markers may refine risk stratification for MPN patients.
